A news release announcing completion of patient follow-up in a late-stage clinical trial of an oral membrane lipid therapy for newly diagnosed glioblastoma; read to learn what trial milestone was reached and what next steps and analyses the article previews.
Key Takeaways
- Phase 2b/3 trial reached last patient, last visit with 144 enrolled glioblastoma patients
- Topline overall survival results are expected in the second quarter of 2027 after data lock
- Safety remained consistent and the LAM561 plus standard of care regimen was well tolerated